Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares: 2020-2025

Historic Preferred Shares for Viridian Therapeutics, Inc.\DE (VRDN) over the last 4 years, with Sep 2025 value amounting to $127.7 million.

  • Viridian Therapeutics, Inc.\DE's Preferred Shares changed negligibly% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.7 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $127.7 million for FY2024, which is 0.46% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Preferred Shares of $127.7 million as of Q3 2025, which was down 0.00% from $127.7 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Preferred Shares' 5-year high stood at $145.8 million during Q3 2021, with a 5-year trough of $78.2 million in Q1 2023.
  • Its 3-year average for Preferred Shares is $114.4 million, with a median of $127.7 million in 2025.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Preferred Shares slumped by 41.38% in 2022 and then surged by 63.97% in 2024.
  • Viridian Therapeutics, Inc.\DE's Preferred Shares (Quarterly) stood at $118.2 million in 2021, then dropped by 27.67% to $85.5 million in 2022, then skyrocketed by 50.09% to $128.3 million in 2023, then fell by 0.46% to $127.7 million in 2024, then remained steady at $127.7 million in 2025.
  • Its last three reported values are $127.7 million in Q3 2025, $127.7 million for Q2 2025, and $127.7 million during Q1 2025.